Victory Capital Management Inc. Boosts Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Victory Capital Management Inc. boosted its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 3.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 262,689 shares of the specialty pharmaceutical company’s stock after acquiring an additional 9,390 shares during the period. Victory Capital Management Inc.’s holdings in Jazz Pharmaceuticals were worth $32,350,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. CWA Asset Management Group LLC purchased a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth $3,197,000. Crossmark Global Holdings Inc. lifted its stake in shares of Jazz Pharmaceuticals by 23.6% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 5,083 shares of the specialty pharmaceutical company’s stock worth $567,000 after purchasing an additional 970 shares during the period. Los Angeles Capital Management LLC purchased a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth $625,000. Venturi Wealth Management LLC lifted its stake in shares of Jazz Pharmaceuticals by 577.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after purchasing an additional 704 shares during the period. Finally, American Assets Inc. purchased a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth $557,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Up 1.7 %

Shares of NASDAQ JAZZ opened at $138.81 on Monday. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $148.06. The company has a market cap of $8.43 billion, a P/E ratio of 19.55, a P/E/G ratio of 1.04 and a beta of 0.44. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock has a fifty day moving average price of $128.14 and a 200 day moving average price of $120.07.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on JAZZ. Cantor Fitzgerald lowered Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and increased their price target for the stock from $140.00 to $150.00 in a research note on Wednesday, February 26th. Needham & Company LLC reissued a “buy” rating and set a $210.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 5th. Morgan Stanley reaffirmed an “overweight” rating and issued a $183.00 target price (up from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday. Piper Sandler reaffirmed an “overweight” rating and issued a $176.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Finally, Robert W. Baird increased their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $189.40.

Insider Activity at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the sale, the chief executive officer now directly owns 439,744 shares in the company, valued at approximately $53,785,088.64. This represents a 0.34 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Neena M. Patil sold 3,800 shares of the firm’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.87, for a total value of $550,506.00. Following the sale, the executive vice president now owns 33,318 shares of the company’s stock, valued at $4,826,778.66. This represents a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 25,193 shares of company stock worth $3,533,122. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.